Just 14 stocks with market caps above $1 billion have doubled so far this year. They probably aren't the winners you would have predicted.

Novo Nordisk NVO and Viking Therapeutics VKTX have emerged as notable players in the obesity space. A market leader in the GLP-1 space, Novo Nordisk markets its semaglutide drugs under brand names ...

(Billable Hours is Reuters' weekly report on lawyers and money. Please send tips or suggestions to ...

In 2023, Novo Nordisk was the most valuable company in Europe, surpassing LVMH on the back of soaring demand for Ozempic and Wegovy. Today, the Danish company has lost its grip on the anti-obesity ...

Regeneron said on Monday its experimental drug helped patients preserve up to 51% of lean mass and lose more fat when used in ...

NEW YORK (Reuters) -Online weight-loss company Noom has begun offering smaller doses of compounded versions of Novo Nordisk's Wegovy as the ... of copies of the in-demand medicine.

"We are introducing Wegovy (injectable Semaglutide 2.4 mg) this year, which offers full therapeutic strengths of semaglutide for comprehensive weight management and obesity treatment," the company ...

The weight loss drug Zepbound (tirzepatide) led to 50 percent more weight loss in a 72-week trial than Wegovy (semaglutide). Participants taking Zepbound lost 50 pounds (lb) on average ...

Wegovy-maker Novo Nordisk has pushed out CEO Lars Fruergaard Jorgensen over concerns the company is losing its first-mover advantage in the highly competitive obesity drug market. Novo Nordisk ...

The company also offers The Body Program — a weight loss program that pairs on-demand virtual medical visits with weight tracking and prescriptions for weight loss medications, including Wegovy.

How Much Does Wegovy Cost With and Without Insurance? This article was reviewed by Craig Primack, MD, FACP, FAAP, FOMA. Wegovy (semaglutide) is approved by the U.S. Food and Drug Administration ...